Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21998010.
- Also identified by DOI 10.1158/0008-5472.CAN-11-1374 and PMC identifier 3201758.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To enable antibodies to function as cytotoxic anticancer agents, they are modified either via attachment to protein toxins or highly potent, low-molecular-weight drugs. Such molecules, termed immunotoxins and antibody-drug conjugates, respectively, represent a second revolution in antibody-mediated cancer therapy. Thus, highly toxic compounds are delivered to the interior of cancer cells based on antibody specificity for cell-surface target antigens.
Medical subject headings
- Antineoplastic Agents
- Hematologic Neoplasms
- Immunotoxins